From the Journals

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

Share

A recent study revealed that stopping sodium-glucose cotransporter-2 (SGLT-2) inhibitors after a urinary tract infection (UTI) in patients with type 2 diabetes may not reduce UTI recurrence but increases the risk of mortality. The research involved 61,606 adults in Hong Kong and showed that those who developed UTIs had a threefold increase in major cardiovascular events and a twofold increase in renal complications. Discontinuing SGLT-2 inhibitors led to higher cardiovascular and renal risks without decreasing UTI incidence, highlighting the importance of continued treatment despite UTIs.

Original Source(s)

Should SGLT-2 Inhibitors Be Continued After a UTI?

Patients with type 2 diabetes who developed urinary tract infections while taking sodium-glucose cotransporter-2 inhibitors faced higher heart and kidney risks.

  • by Kathryn Wighton

  • November 4, 2025

  • 3 min

Related Content

Plozasiran Wins FDA Nod for FCS

Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.

Waist Circumference Link to DR

Obesity measure linked to diabetic retinopathy risk in US adults

Testing Metformin’s Reach in PAD

Double-blind trial of 202 patients shows no improvement in 6-minute walk distance at 6 months compared with placebo.